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In a nested-case control study of 100 cases of gastric cancer and 400 matched controls in relation to virulence factors of Helicobacter
pylori in a Korean cohort, CagA seropositivity was significantly associated with a higher risk of gastric cancer among H. pylori-infected
subjects (OR¼3.57, 95% CI 1.05–12.14).
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Gastric cancer is the first major incident cancer with an age-
standardized incidence rate of 69.6 in males and 26.8 in females
per 100000 in Korea, the highest in the world (Ferlay et al, 2004;
Shin et al, 2005b). Helicobacter pylori (HP) was classified as a
group I human carcinogen for gastric cancer by the International
Agency for Research on Cancer in 1994 (IARC, 1994). However,
despite the evidence that HP infection increases gastric cancer risk,
the prevalence of HP infection does not always correlate positively
with risk (Uemura et al, 2001; Peek and Blaser, 2002; Lunet and
Barros, 2003). In fact, certain Asian and African countries with a
high prevalence of HP infection have a low incidence of gastric
cancer (Lunet and Barros, 2003).
One explanation for the above differences concerns virulence
factors, such as cytotoxin-associated antigen (CagA) and vacuolat-
ing cytotoxin (VacA), produced by HP strains, that may be more
carcinogenic to the gastric epithelium (Peek and Blaser, 2002).
These factors can invade epithelial cells in stomach walls and
induce epithelial responses with carcinogenic potential (Peek and
Crabtree, 2006).
We previously reported a null association between HP infection
and gastric cancer in a nested case–control study within the
Korean Multi-Center Cancer Cohort (KMCC) (Shin et al, 2005a).
We have therefore investigated the virulence factors, CagA and/or
VacA seropositivity, in relation to gastric cancer susceptibility.
MATERIALS AND METHODS
The Korean Multi-Center Cancer Cohort (KMCC) is a prospective
cancer cohort based on four urban or rural areas in Korea (Yoo
et al, 2002). Participants over age 30 years were recruited from
1993 through 2004. A detailed standardized questionnaire on
general lifestyle, physical activity, dietary habit, reproductive
factors, and past medical history was completed for each subject
by interviewers at the time of recruitment. Blood and urine
samples were donated voluntarily. Blood samples were then stored
at  701C and urine samples at  201C. The study protocol was
approved by the Institutional Review Boards of the Seoul National
University Hospital and the National Cancer Center of Korea. All
subjects provided written informed consent.
As of December 2002, 136 gastric cancer cases were identified
among the 14,440 cohort members through a computerized record
linkage to the Korea Central Cancer Registry database and the
National Health Insurance database. Of these, we excluded gastric
cancer cases diagnosed before recruitment (n¼36). To validate a
diagnosis of gastric cancer and to obtain additional detailed
clinical information such as tumour site, a medical record review
was undertaken in all such cases. For comparison, four controls
from the eligible cancer-free cohort were matched to each cancer
case by incidence density sampling based on age (within 5 years),
gender, area of residence and the year of recruitment.
Sera were assayed using immunoblot kits (Helico Blot 2.1t,M P
Biomedicals Asia Pacific, Singapore) to identify IgG anti-
bodies specific for HP according to the manufacturer’s instruction.
CagA and VacA seropositivity and HP infection status were
determined using these kits. Sensitivities for HP infection, and
CagA and VacA seropositivities have been reported to be 99, 99
and 93%, and specificities to be 98, 90 and 88%, respectively (Park
et al, 2002).
The demographic characteristics of cases and controls were
compared using the w
2 test. Conditional logistic regression models
were used to calculate odds ratios (ORs) and 95% confidence
intervals (CIs). In subgroup analyses stratified by HP IgG
antibody, unconditional logistic regression models were used
because the matches of cases and controls were not preserved after
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ystratification. ORs were adjusted for smoking history, alcohol
consumption, years of education and matching variables. Sub-
group analyses stratified by follow-up period (o2.4 years vs X2.4
years) were also undertaken. All statistical analyses were
performed using SAS v9.1.
RESULTS
Table 1 shows the baseline characteristics of the study subjects.
The mean age of cases was 63 years and two-thirds were male. Of
the cases, 34% were never-smokers and 44% never-drinkers and
27% were uneducated. Smoking history and alcohol drinking
history, and years of education were not significantly different
between cases and controls. In all, 75 cases were non-cardiac
gastric cancer and 87 were adenocarcinoma. The median interval
from initial blood collection to the diagnosis of gastric cancer was
2.4 years.
Table 2 shows the OR for gastric cancer in relation to HP
infection and the virulence factors. HP infection was present in
89% of cases and 90% of controls. Overall, HP infection was not
found to be associated with gastric cancer (OR¼0.96, 95% CI
0.68–1.36). CagA and VacA seropositivity was not found to elevate
the risk of gastric cancer (OR¼1.10, 95% CI 0.83–1.47; OR¼1.04,
95% CI 0.85–1.28, respectively). The risk of HP infection and CagA
and VacA seropositivity were not found to be significantly
different for gender (male vs female) and the period of follow-up
(o2.4 vs X2.4 years) (data not shown).
The associations of CagA and VacA seropositivity on the risk for
gastric cancer were evaluated stratified by HP IgG antibody
(Table 3). Among HP-infected subjects, o10% of them were
infected with CagA-negative strains. CagA seropositivity was
significantly associated with gastric cancer risk among HP-infected
subjects (OR¼3.74, 95% CI 1.10–12.73), although not among
HP-negative subjects (OR¼0.96, CI 0.08–11.66). There was no
significant interaction between HP and CagA (p-inter-
action¼0.245). VacA seropositivity insignificantly increased the
risk of gastric cancer among HP-infected subjects (OR¼1.38, 95%
CI 0.81–2.35). However, because there was no subject who was
H. pylori-negative and VacA-positive, the interaction between
H. pylori and VacA could not be evaluated.
DISCUSSION
This nested case–control study suggests that CagA-producing HP
increases the risk of gastric cancer in the Korean population. There
was no evidence, however, of any significant statistical interaction
Table 1 Baseline characteristics of the gastric cancer patients and
controls
Cases (n¼100)
No. (%)
Controls
(n¼400) No. (%) P-value*
Gender
Female 33 (33) 132 (33)
Male 67 (67) 268 (67) 1.00
Age (year)
o65 60 (60) 252 (63)
X65 40 (40) 148 (37) 0.58
Smoking history
Never smoker 34 (34) 171 (43)
Ex-smoker 14 (14) 58 (15)
Current smoker 52 (52) 171 (43) 0.22
Alcohol consumption
Never drinker 44 (44) 179 (45)
Ex-drinker 12 (12) 33 (8)
Current drinker 44 (44) 188 (47) 0.49
Education (year)
No education 27 (27) 111 (29)
1–12 71 (71) 283 (71)
X13 2 (2) 6 (2) 0.93
Follow-up duration until diagnosis (year)
o2.0 37 (37)
2.0–4.9 46 (46)
X5.0 17 (17)
Tumour sites
Cardia 7 (7)
Non-cardia 75 (75)
Unspecified 18 (18)
Tumour pathology
Adenocarcinoma 87 (87)
Others 3 (3)
Unspecified 10 (10)
*P-values were calculated using the w
2 test.
Table 2 Odds ratios and 95% confidence intervals for gastric cancer
according to the presence of H. pylori IgG antibody and CagA and VacA
seropositivity
Subgroups Cases No. (%)
Controls No.
(%)
aOR
a (95%
CI
b)
H. pylori
Negative 11 (11) 40 (10) 1.0
Positive 89 (89) 360 (90) 0.96 (0.68–1.36)
CagA
Negative 10 (10) 63 (16) 1.0
Positive 90 (90) 337 (84) 1.10 (0.83–1.47)
VacA
Negative 36 (36) 158 (40) 1.0
Positive 64 (64) 242 (61) 1.04 (0.85–1.28)
aOdds ratios were adjusted for smoking, alcohol, education using conditional logistic
regression model.
bCI: confidence intervals.
Table 3 Odds ratios and 95% confidence intervals for gastric cancer
according to the CagA and VacA seropositivity stratified by H. pylori IgG
Subgroups Cases No. (%) Controls No. (%) aOR
a (95% CI
b)
H. pylori positive
CagA
Negative 3 (3) 35 (10) 1.0
Positive 86 (97) 325 (90) 3.74 (1.10–12.73)
VacA
Negative 25 (28) 117 (33) 1.0
Positive 64 (72) 243 (68) 1.38 (0.81–2.35)
CagA & VacA
Others 27 (30) 133 (37) 1.0
Both positive 62 (70) 227 (63) 1.48 (0.88–2.49)
H. pylori negative
CagA
Negative 7 (64) 28 (70) 1.0
Positive 4 (36) 12 (30) 0.96 (0.08–11.66)
VacA
Negative 11 (100) 40 (100)
Positive 0 (0) 0 (0) — —
aOdds ratios adjusted for age, gender, smoking, alcohol, education, area of residence
and the year of recruitment using unconditional logistic regression model.
bCI:
confidence intervals.
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as being more virulent with respect to atrophic gastritis, intestinal
metaplasia and gastric cancer development (Hatakeyama, 2004). It
may also be relevant that in the Mongolian gerbil, CagA-positive
HP strains caused more severe inflammation in gastric mucosa
than did CagA-negative strains (Dhar et al, 2003).
In a recent meta-analysis of 16 epidemiologic studies, the overall
OR for CagA seropositivity among HP-infected subjects was 1.49
(95% CI 1.25–1.77) (Huang et al, 2003). Several studies have failed
to detect a positive association between VacA protein sero-
positivity and gastric cancer risk (Shimoyama et al, 1999; Yamaoka
et al, 1999), although Rudi et al (1997) reported an elevated risk of
gastric cancer (OR¼1.74, 95% CI 1.08–2.78) in VacA seropositive
participants (Rudi et al, 1997).
The risk of gastric cancer associated with CagA observed in the
present study was higher than that in the meta-analysis by Huang
et al. It has been suggested that the distribution and patho-
genicities of HP subtypes found in East Asia differ from those
found in Western countries (Hatakeyama, 2004). In Europe and
the US the cagA1 subtype of the cagA gene is dominant, whereas
the cagA2 subtype, which is more biologically active and virulent,
is exclusively found in East Asia (Gonzalez et al, 2003). Genotypes
for CagA were not investigated in the present study. Nevertheless,
if the majority of HP strains infecting the Korean population are
the cagA2 subtype, the higher risk found in the present study than
in Western studies concurs with the putative mechanistic role of
this subtype in gastric carcinogenesis.
Prospective and community-based cohort design of the present
study minimized the possibility of misclassification for exposure.
Using the residence registration number, which is a unique
identifier for each individual in Korea, the follow-up data linkages
were established and enabled complete identification of cancer
development status and death.
However, the study also has certain limitations. The small
number of gastric cancer patients (n¼100) and the low frequency
of HP-negative subjects (10%) limits the statistical power to evaluate
the effect of HP infection and virulence factors. The misclassifica-
tion of exposure to HP infection due to seroreversion of HP in the
elderly with gastric atrophy and the relatively short period of follow-
up might have influenced our results (Kikuchi, 2002). But the risks
of HP infection and virulence factors were not significantly different
for the follow-up period (o2.4 vs X2.4 years). The direction
of its influence, if it existed, would have been toward the null.
Measurement of serum pepsinogen I and II levels would have been
helpful in terms of identifying participants with premalignant
lesions and preventing the misclassification (Watabe et al, 2005).
Our study suggests that CagA-producing HP increases the risk
of gastric cancer in the Korean population, although it should be
noted that a large proportion of healthy controls are also infected
with CagA- or VacA-producing HP. Some nutrients, food
components and host genetic polymorphisms may be involved in
gastric carcinogenesis associated with HP infection (Hamajima,
2003; Correa, 2004). Further studies on individual genetic
susceptibilities and dietary habits, and on the effects of bacterial
variants should be pursued.
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